Drugs & Targets CHMP recommends approval for selumetinib in the EU as first medicine for pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas April 30, 2021Vol.47 No.17
Drugs & Targets European Commission approves GSK’s Jemperli, the first anti-PD-1 therapy approved for recurrent or advanced endometrial cancer April 30, 2021Vol.47 No.17
Drugs & Targets Inivata, Agendia sign agreement for commercialization of RaDaR MRD liquid biopsy assay in breast cancer April 30, 2021Vol.47 No.17
Drugs & Targets Jemperli receives FDA accelerated approval for endometrial cancer April 23, 2021Vol.47 No.16
Drugs & Targets Opdivo + chemo regimen gets FDA approval for metastatic gastric cancer, esophageal adenocarcinoma indications April 23, 2021Vol.47 No.16
Drugs & Targets Bemarituzumab receives Breakthrough Therapy designation from FDA April 23, 2021Vol.47 No.16
Drugs & Targets European Commission approves second indication of Sarclisa for relapsed multiple myeloma April 23, 2021Vol.47 No.16
Drugs & Targets NeoGenomics establishes Biomarker Assist KRAS Single Gene Testing Program for advanced NSCLC April 23, 2021Vol.47 No.16
Drugs & Targets Trodelvy receives FDA accelerated approval for advanced urothelial cancer April 16, 2021Vol.47 No.15
Drugs & Targets GI Genius receives marketing authorization from FDA to detect potential signs of colon cancer April 16, 2021Vol.47 No.15
